Ossiam Increases Stock Holdings in Kenvue Inc. $KVUE

Key Points

• Ossiam boosted its position in Kenvue by 10.2% in Q3 to 1,468,938 shares, worth about $23.84M (roughly 0.08% of the company).
• Kenvue beat quarterly estimates with $0.27 EPS vs $0.22 and $3.78B revenue (+3.2% YoY), and pays a quarterly dividend of $0.2075 (annualized yield ~4.7%, payout ratio 107.8%).
• Institutional investors own 97.64% of Kenvue (Vanguard holds ~233.25M shares, ~$4.88B), and analysts' consensus is a "Hold" with an average price target of $19.58.

Ossiam boosted its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 10.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,468,938 shares of the company's stock after acquiring an additional 136,041 shares during the period. Ossiam owned 0.08% of Kenvue worth $23,841,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in Kenvue by 1.8% during the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company's stock valued at $4,881,844,000 after purchasing an additional 4,101,880 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Kenvue by 27.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 310,686 shares of the company's stock worth $5,042,000 after buying an additional 66,192 shares in the last quarter. Renaissance Capital LLC increased its holdings in shares of Kenvue by 55.8% in the 3rd quarter. Renaissance Capital LLC now owns 980,436 shares of the company's stock worth $15,912,000 after buying an additional 351,259 shares during the last quarter. Viking Fund Management LLC raised its position in shares of Kenvue by 36.0% during the 3rd quarter. Viking Fund Management LLC now owns 605,000 shares of the company's stock valued at $9,819,000 after buying an additional 160,000 shares in the last quarter. Finally, Allstate Corp purchased a new stake in shares of Kenvue during the 3rd quarter valued at $1,152,000. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

KVUE stock opened at $17.51 on Friday. The stock has a market capitalization of $33.55 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 3.95 and a beta of 0.51. The firm's 50-day moving average price is $17.89 and its two-hundred day moving average price is $17.32. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion during the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. Kenvue's revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 earnings per share. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue's dividend payout ratio (DPR) is 107.79%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KVUE. Canaccord Genuity Group increased their target price on Kenvue from $17.00 to $18.00 and gave the company a "hold" rating in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Kenvue in a research note on Friday, January 9th. Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the stock an "equal weight" rating in a report on Friday, March 6th. Jefferies Financial Group lowered Kenvue from a "buy" rating to a "hold" rating and lowered their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Finally, Argus upgraded Kenvue to a "hold" rating in a report on Friday, March 6th. Three analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.